Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 261

1.

Taking up the reins of power: metabolic functions of p53.

Humpton T, Vousden K.

J Mol Cell Biol. 2019 Jul 8. pii: mjz065. doi: 10.1093/jmcb/mjz065. [Epub ahead of print] No abstract available.

PMID:
31282931
2.

Oncogenic Kras induces Nix-mediated mitophagy to promote pancreatic cancer.

Humpton TJ, Alagesan B, DeNicola GM, Lu D, Yordanov GN, Leonhardt CS, Yao MA, Alagesan P, Zaatari MN, Park Y, Skepper JN, Macleod KF, Perez-Mancera PA, Murphy MP, Evan GI, Vousden KH, Tuveson DA.

Cancer Discov. 2019 Jul 1. pii: CD-18-1409. doi: 10.1158/2159-8290.CD-18-1409. [Epub ahead of print]

PMID:
31263025
3.

Brexit negotiations: what is next for science?

Vousden KH.

EMBO Rep. 2019 Apr;20(4). pii: e48026. doi: 10.15252/embr.201948026. Epub 2019 Mar 15. No abstract available.

PMID:
30877135
4.

Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1.

Vousden KA, Lundqvist T, Popovic B, Naiman B, Carruthers AM, Newton P, Johnson DJD, Pomowski A, Wilkinson T, Dufner P, de Mendez I, Mallinder PR, Murray C, Strain M, Connor J, Murray LA, Sleeman MA, Lowe DC, Huntington JA, Vaughan TJ.

Sci Rep. 2019 Feb 7;9(1):1605. doi: 10.1038/s41598-019-38842-x.

5.

Use of 13C315N1-Serine or 13C515N1-Methionine for Studying Methylation Dynamics in Cancer Cell Metabolism and Epigenetics.

Newman AC, Labuschagne CF, Vousden KH, Maddocks ODK.

Methods Mol Biol. 2019;1928:55-67. doi: 10.1007/978-1-4939-9027-6_4.

PMID:
30725450
6.

p53-mediated adaptation to serine starvation is retained by a common tumour-derived mutant.

Humpton TJ, Hock AK, Maddocks ODK, Vousden KH.

Cancer Metab. 2018 Dec 3;6:18. doi: 10.1186/s40170-018-0191-6. eCollection 2018.

7.

Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels.

Novo D, Heath N, Mitchell L, Caligiuri G, MacFarlane A, Reijmer D, Charlton L, Knight J, Calka M, McGhee E, Dornier E, Sumpton D, Mason S, Echard A, Klinkert K, Secklehner J, Kruiswijk F, Vousden K, Macpherson IR, Blyth K, Bailey P, Yin H, Carlin LM, Morton J, Zanivan S, Norman JC.

Nat Commun. 2018 Nov 29;9(1):5069. doi: 10.1038/s41467-018-07339-y.

8.

Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responses.

Chen B, Vousden KA, Naiman B, Turman S, Sun H, Wang S, Vinall LMK, Kemp BP, Kasturiangan S, Rees DG, Grant E, Hinrichs MJ, Eck S, DiGiandomenico A, Jack Borrok M, Ly N, Xiong X, Gonzalez C, Morehouse C, Wang Y, Zhou Y, Cann J, Zhao W, Koelkebeck H, Okubo K, Mayadas TN, Howe D, Griffiths J, Kolbeck R, Herbst R, Sims GP.

Ann Rheum Dis. 2019 Feb;78(2):228-237. doi: 10.1136/annrheumdis-2018-213523. Epub 2018 Nov 20.

9.

Direct Estimation of Metabolic Flux by Heavy Isotope Labeling Simultaneous with Pathway Inhibition: Metabolic Flux Inhibition Assay.

Zhang T, Labuschagne CF, Vousden KH, Maddocks ODK.

Methods Mol Biol. 2019;1862:109-119. doi: 10.1007/978-1-4939-8769-6_8.

PMID:
30315463
10.

A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3.

Tajan M, Hock AK, Blagih J, Robertson NA, Labuschagne CF, Kruiswijk F, Humpton TJ, Adams PD, Vousden KH.

Cell Metab. 2018 Nov 6;28(5):721-736.e6. doi: 10.1016/j.cmet.2018.07.005. Epub 2018 Aug 16.

11.

Finding clues in the p53 maze: an interview with Karen Vousden.

Vousden K.

Dis Model Mech. 2018 Jul 27;11(8). pii: dmm035675. doi: 10.1242/dmm.035675.

12.

The ERBB network facilitates KRAS-driven lung tumorigenesis.

Kruspig B, Monteverde T, Neidler S, Hock A, Kerr E, Nixon C, Clark W, Hedley A, Laing S, Coffelt SB, Le Quesne J, Dick C, Vousden KH, Martins CP, Murphy DJ.

Sci Transl Med. 2018 Jun 20;10(446). pii: eaao2565. doi: 10.1126/scitranslmed.aao2565. Erratum in: Sci Transl Med. 2018 Nov 21;10(468):.

PMID:
29925636
13.

Control of metabolism by p53 - Cancer and beyond.

Labuschagne CF, Zani F, Vousden KH.

Biochim Biophys Acta Rev Cancer. 2018 Aug;1870(1):32-42. doi: 10.1016/j.bbcan.2018.06.001. Epub 2018 Jun 5. Review.

14.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G.

Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23. Review.

15.

ΔNp63-mediated regulation of hyaluronic acid metabolism and signaling supports HNSCC tumorigenesis.

Compagnone M, Gatti V, Presutti D, Ruberti G, Fierro C, Markert EK, Vousden KH, Zhou H, Mauriello A, Anemone L, Bongiorno-Borbone L, Melino G, Peschiaroli A.

Proc Natl Acad Sci U S A. 2017 Dec 12;114(50):13254-13259. doi: 10.1073/pnas.1711777114. Epub 2017 Nov 21.

16.

Spontaneous Secretion of the Citrullination Enzyme PAD2 and Cell Surface Exposure of PAD4 by Neutrophils.

Zhou Y, Chen B, Mittereder N, Chaerkady R, Strain M, An LL, Rahman S, Ma W, Low CP, Chan D, Neal F, Bingham CO 3rd, Sampson K, Darrah E, Siegel RM, Hasni S, Andrade F, Vousden KA, Mustelin T, Sims GP.

Front Immunol. 2017 Sep 25;8:1200. doi: 10.3389/fimmu.2017.01200. eCollection 2017.

17.

Corrigendum: Modulating the therapeutic response of tumours to dietary serine and glycine starvation.

Maddocks ODK, Athineos D, Cheung EC, Lee P, Zhang T, van den Broek NJF, Mackay GM, Labuschagne CF, Gay D, Kruiswijk F, Blagih J, Vincent DF, Campbell KJ, Ceteci F, Sansom OJ, Blyth K, Vousden KH.

Nature. 2017 Aug 2;548(7665):122. doi: 10.1038/nature23471.

PMID:
28770843
18.

Structural analysis of MDM2 RING separates degradation from regulation of p53 transcription activity.

Nomura K, Klejnot M, Kowalczyk D, Hock AK, Sibbet GJ, Vousden KH, Huang DT.

Nat Struct Mol Biol. 2017 Jul;24(7):578-587. doi: 10.1038/nsmb.3414. Epub 2017 May 29.

19.

Development of an inducible mouse model of iRFP713 to track recombinase activity and tumour development in vivo.

Hock AK, Cheung EC, Humpton TJ, Monteverde T, Paulus-Hock V, Lee P, McGhee E, Scopelliti A, Murphy DJ, Strathdee D, Blyth K, Vousden KH.

Sci Rep. 2017 May 12;7(1):1837. doi: 10.1038/s41598-017-01741-0.

20.

Modulating the therapeutic response of tumours to dietary serine and glycine starvation.

Maddocks ODK, Athineos D, Cheung EC, Lee P, Zhang T, van den Broek NJF, Mackay GM, Labuschagne CF, Gay D, Kruiswijk F, Blagih J, Vincent DF, Campbell KJ, Ceteci F, Sansom OJ, Blyth K, Vousden KH.

Nature. 2017 Apr 19;544(7650):372-376. doi: 10.1038/nature22056. Erratum in: Nature. 2017 Aug 2;548(7665):122.

PMID:
28425994
21.

One carbon, many roads.

Gottlieb E, Vousden KH.

Cell Death Differ. 2017 Feb;24(2):193-194. doi: 10.1038/cdd.2016.160. Epub 2017 Jan 6. No abstract available.

22.

The Quid Pro Quo of the Tumor/Stromal Interaction.

Tajan M, Vousden KH.

Cell Metab. 2016 Nov 8;24(5):645-646. doi: 10.1016/j.cmet.2016.10.017.

23.

Serine one-carbon catabolism with formate overflow.

Meiser J, Tumanov S, Maddocks O, Labuschagne CF, Athineos D, Van Den Broek N, Mackay GM, Gottlieb E, Blyth K, Vousden K, Kamphorst JJ, Vazquez A.

Sci Adv. 2016 Oct 28;2(10):e1601273. eCollection 2016 Oct.

24.

Serine and one-carbon metabolism in cancer.

Yang M, Vousden KH.

Nat Rev Cancer. 2016 Oct;16(10):650-62. doi: 10.1038/nrc.2016.81. Epub 2016 Sep 16. Review.

PMID:
27634448
25.

Location, location, location.

Vousden KH, Yang M.

Science. 2016 Sep 9;353(6304):1095-6. doi: 10.1126/science.aai7629. No abstract available.

PMID:
27609873
26.

CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.

Walton J, Blagih J, Ennis D, Leung E, Dowson S, Farquharson M, Tookman LA, Orange C, Athineos D, Mason S, Stevenson D, Blyth K, Strathdee D, Balkwill FR, Vousden K, Lockley M, McNeish IA.

Cancer Res. 2016 Oct 15;76(20):6118-6129. Epub 2016 Aug 16.

27.

Intrinsic aggregation propensity of the p63 and p73 TI domains correlates with p53R175H interaction and suggests further significance of aggregation events in the p53 family.

Kehrloesser S, Osterburg C, Tuppi M, Schäfer B, Vousden KH, Dötsch V.

Cell Death Differ. 2016 Dec;23(12):1952-1960. doi: 10.1038/cdd.2016.75. Epub 2016 Jul 22.

28.

Regulation of Cellular Metabolism and Hypoxia by p53.

Humpton TJ, Vousden KH.

Cold Spring Harb Perspect Med. 2016 Jul 1;6(7). pii: a026146. doi: 10.1101/cshperspect.a026146. Review.

29.

Serine Metabolism Supports the Methionine Cycle and DNA/RNA Methylation through De Novo ATP Synthesis in Cancer Cells.

Maddocks OD, Labuschagne CF, Adams PD, Vousden KH.

Mol Cell. 2016 Jan 21;61(2):210-21. doi: 10.1016/j.molcel.2015.12.014. Epub 2016 Jan 7.

30.

Opposing effects of TIGAR- and RAC1-derived ROS on Wnt-driven proliferation in the mouse intestine.

Cheung EC, Lee P, Ceteci F, Nixon C, Blyth K, Sansom OJ, Vousden KH.

Genes Dev. 2016 Jan 1;30(1):52-63. doi: 10.1101/gad.271130.115. Epub 2015 Dec 17.

31.

Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation.

Cohen ES, Scott IC, Majithiya JB, Rapley L, Kemp BP, England E, Rees DG, Overed-Sayer CL, Woods J, Bond NJ, Veyssier CS, Embrey KJ, Sims DA, Snaith MR, Vousden KA, Strain MD, Chan DT, Carmen S, Huntington CE, Flavell L, Xu J, Popovic B, Brightling CE, Vaughan TJ, Butler R, Lowe DC, Higazi DR, Corkill DJ, May RD, Sleeman MA, Mustelin T.

Nat Commun. 2015 Sep 14;6:8327. doi: 10.1038/ncomms9327.

32.

PHD1 regulates p53-mediated colorectal cancer chemoresistance.

Deschoemaeker S, Di Conza G, Lilla S, Martín-Pérez R, Mennerich D, Boon L, Hendrikx S, Maddocks OD, Marx C, Radhakrishnan P, Prenen H, Schneider M, Myllyharju J, Kietzmann T, Vousden KH, Zanivan S, Mazzone M.

EMBO Mol Med. 2015 Oct;7(10):1350-65. doi: 10.15252/emmm.201505492.

33.

p53- and p73-independent activation of TIGAR expression in vivo.

Lee P, Hock AK, Vousden KH, Cheung EC.

Cell Death Dis. 2015 Aug 6;6:e1842. doi: 10.1038/cddis.2015.205.

34.

p53 in survival, death and metabolic health: a lifeguard with a licence to kill.

Kruiswijk F, Labuschagne CF, Vousden KH.

Nat Rev Mol Cell Biol. 2015 Jul;16(7):393-405. doi: 10.1038/nrm4007. Review.

PMID:
26122615
35.

Hitting cancers' weak spots: vulnerabilities imposed by p53 mutation.

Gurpinar E, Vousden KH.

Trends Cell Biol. 2015 Aug;25(8):486-95. doi: 10.1016/j.tcb.2015.04.001. Epub 2015 May 7. Review.

PMID:
25960041
36.

A roadmap for interpreting (13)C metabolite labeling patterns from cells.

Buescher JM, Antoniewicz MR, Boros LG, Burgess SC, Brunengraber H, Clish CB, DeBerardinis RJ, Feron O, Frezza C, Ghesquiere B, Gottlieb E, Hiller K, Jones RG, Kamphorst JJ, Kibbey RG, Kimmelman AC, Locasale JW, Lunt SY, Maddocks OD, Malloy C, Metallo CM, Meuillet EJ, Munger J, Nöh K, Rabinowitz JD, Ralser M, Sauer U, Stephanopoulos G, St-Pierre J, Tennant DA, Wittmann C, Vander Heiden MG, Vazquez A, Vousden K, Young JD, Zamboni N, Fendt SM.

Curr Opin Biotechnol. 2015 Aug;34:189-201. doi: 10.1016/j.copbio.2015.02.003. Epub 2015 Feb 28. Review.

37.

Ubiquitination and proteasomal degradation of ATG12 regulates its proapoptotic activity.

Haller M, Hock AK, Giampazolias E, Oberst A, Green DR, Debnath J, Ryan KM, Vousden KH, Tait SW.

Autophagy. 2014;10(12):2269-78. doi: 10.4161/15548627.2014.981914.

38.

Functional interplay between MDM2, p63/p73 and mutant p53.

Stindt MH, Muller PA, Ludwig RL, Kehrloesser S, Dötsch V, Vousden KH.

Oncogene. 2015 Aug 13;34(33):4300-10. doi: 10.1038/onc.2014.359. Epub 2014 Nov 24.

39.

Ubiquitin-specific peptidase 42 (USP42) functions to deubiquitylate histones and regulate transcriptional activity.

Hock AK, Vigneron AM, Vousden KH.

J Biol Chem. 2014 Dec 12;289(50):34862-70. doi: 10.1074/jbc.M114.589267. Epub 2014 Oct 21.

40.

Metabolic effect of TAp63α: enhanced glycolysis and pentose phosphate pathway, resulting in increased antioxidant defense.

D'Alessandro A, Amelio I, Berkers CR, Antonov A, Vousden KH, Melino G, Zolla L.

Oncotarget. 2014 Sep 15;5(17):7722-33.

41.

Localization of NADPH production: a wheel within a wheel.

Maddocks OD, Labuschagne CF, Vousden KH.

Mol Cell. 2014 Jul 17;55(2):158-60. doi: 10.1016/j.molcel.2014.07.001. Erratum in: Mol Cell. 2014 Nov 20;56(4):608.

42.

iRFP is a real time marker for transformation based assays in high content screening.

Paulus-Hock V, Cheung EC, Roxburgh P, Vousden KH, Hock AK.

PLoS One. 2014 Jun 2;9(6):e98399. doi: 10.1371/journal.pone.0098399. eCollection 2014.

43.

Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells.

Labuschagne CF, van den Broek NJ, Mackay GM, Vousden KH, Maddocks OD.

Cell Rep. 2014 May 22;7(4):1248-58. doi: 10.1016/j.celrep.2014.04.045. Epub 2014 May 10.

44.

Mutant p53 in cancer: new functions and therapeutic opportunities.

Muller PA, Vousden KH.

Cancer Cell. 2014 Mar 17;25(3):304-17. doi: 10.1016/j.ccr.2014.01.021. Review.

45.

Endogenous c-Myc is essential for p53-induced apoptosis in response to DNA damage in vivo.

Phesse TJ, Myant KB, Cole AM, Ridgway RA, Pearson H, Muncan V, van den Brink GR, Vousden KH, Sears R, Vassilev LT, Clarke AR, Sansom OJ.

Cell Death Differ. 2014 Jun;21(6):956-66. doi: 10.1038/cdd.2014.15. Epub 2014 Feb 28.

46.

TIGAR, TIGAR, burning bright.

Lee P, Vousden KH, Cheung EC.

Cancer Metab. 2014 Jan 3;2(1):1. doi: 10.1186/2049-3002-2-1.

47.

Mutant p53 regulates Dicer through p63-dependent and -independent mechanisms to promote an invasive phenotype.

Muller PA, Trinidad AG, Caswell PT, Norman JC, Vousden KH.

J Biol Chem. 2014 Jan 3;289(1):122-32. doi: 10.1074/jbc.M113.502138. Epub 2013 Nov 12.

48.

iRFP is a sensitive marker for cell number and tumor growth in high-throughput systems.

Hock AK, Lee P, Maddocks OD, Mason SM, Blyth K, Vousden KH.

Cell Cycle. 2014;13(2):220-6. doi: 10.4161/cc.26985. Epub 2013 Oct 31.

49.

5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2.

Dickens MP, Roxburgh P, Hock A, Mezna M, Kellam B, Vousden KH, Fischer PM.

Bioorg Med Chem. 2013 Nov 15;21(22):6868-77. doi: 10.1016/j.bmc.2013.09.038. Epub 2013 Sep 25.

50.

Twenty-fifth annual Pezcoller Symposium: Metabolism and tumorigenesis.

Kaelin W, Livingston D, Loda M, Vousden K, Mihich E.

Cancer Res. 2013 Oct 15;73(20):6124-7. doi: 10.1158/0008-5472.CAN-13-2445. Epub 2013 Oct 4.

Supplemental Content

Loading ...
Support Center